159 related articles for article (PubMed ID: 28350129)
1. Apoptosis is augmented in high-grade serous ovarian cancer by the combined inhibition of Bcl-2/Bcl-xL and PARP.
Yokoyama T; Kohn EC; Brill E; Lee JM
Int J Oncol; 2017 Apr; 50(4):1064-1074. PubMed ID: 28350129
[TBL] [Abstract][Full Text] [Related]
2. Antagonism of Bcl-XL is necessary for synergy between carboplatin and BH3 mimetics in ovarian cancer cells.
Abed MN; Abdullah MI; Richardson A
J Ovarian Res; 2016 Apr; 9():25. PubMed ID: 27080533
[TBL] [Abstract][Full Text] [Related]
3. Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases
Brill E; Yokoyama T; Nair J; Yu M; Ahn YR; Lee JM
Oncotarget; 2017 Dec; 8(67):111026-111040. PubMed ID: 29340034
[TBL] [Abstract][Full Text] [Related]
4. Identification of predictive factors of response to the BH3-mimetic molecule ABT-737: an ex vivo experiment in human serous ovarian carcinoma.
Lheureux S; N'Diaye M; Blanc-Fournier C; Dugué AE; Clarisse B; Dutoit S; Giffard F; Abeilard E; Briand M; Labiche A; Grellard JM; Crouet H; Martin S; Joly F; Poulain L
Int J Cancer; 2015 Mar; 136(5):E340-50. PubMed ID: 25066666
[TBL] [Abstract][Full Text] [Related]
5. Induction of Noxa sensitizes human colorectal cancer cells expressing Mcl-1 to the small-molecule Bcl-2/Bcl-xL inhibitor, ABT-737.
Okumura K; Huang S; Sinicrope FA
Clin Cancer Res; 2008 Dec; 14(24):8132-42. PubMed ID: 19088028
[TBL] [Abstract][Full Text] [Related]
6. Phenethyl Isothiocyanate Enhances the Cytotoxic Effects of PARP Inhibitors in High-Grade Serous Ovarian Cancer Cells.
Jia Y; Wang M; Sang X; Liu P; Gao J; Jiang K; Cheng H
Front Oncol; 2021; 11():812264. PubMed ID: 35155204
[TBL] [Abstract][Full Text] [Related]
7. Synergistic activity of ABT-263 and ONC201/TIC10 against solid tumor cell lines is associated with suppression of anti-apoptotic Mcl-1, BAG3, pAkt, and upregulation of pro-apoptotic Noxa and Bax cleavage during apoptosis.
Di Cristofano FR; Fong MW; Huntington KE; Carneiro BA; Zhou L; El-Deiry WS
Am J Cancer Res; 2023; 13(1):307-325. PubMed ID: 36777502
[TBL] [Abstract][Full Text] [Related]
8. Combined MEK and BCL-2/X
Iavarone C; Zervantonakis IK; Selfors LM; Palakurthi S; Liu JF; Drapkin R; Matulonis UA; Hallberg D; Velculescu VE; Leverson JD; Sampath D; Mills GB; Brugge JS
Mol Cancer Ther; 2019 Mar; 18(3):642-655. PubMed ID: 30679390
[TBL] [Abstract][Full Text] [Related]
9. ABT-263 induces G
Lin QH; Que FC; Gu CP; Zhong DS; Zhou D; Kong Y; Yu L; Liu SW
Acta Pharmacol Sin; 2017 Dec; 38(12):1632-1641. PubMed ID: 28713162
[TBL] [Abstract][Full Text] [Related]
10. γ-Secretase inhibition promotes cell death, Noxa upregulation, and sensitization to BH3 mimetic ABT-737 in human breast cancer cells.
Séveno C; Loussouarn D; Bréchet S; Campone M; Juin P; Barillé-Nion S
Breast Cancer Res; 2012 Jun; 14(3):R96. PubMed ID: 22703841
[TBL] [Abstract][Full Text] [Related]
11. Synergistic induction of apoptosis by the Bcl-2 inhibitor ABT-737 and imatinib mesylate in gastrointestinal stromal tumor cells.
Reynoso D; Nolden LK; Yang D; Dumont SN; Conley AP; Dumont AG; Zhou K; Duensing A; Trent JC
Mol Oncol; 2011 Feb; 5(1):93-104. PubMed ID: 21115411
[TBL] [Abstract][Full Text] [Related]
12. The combination of a sphingosine kinase 2 inhibitor (ABC294640) and a Bcl-2 inhibitor (ABT-199) displays synergistic anti-myeloma effects in myeloma cells without a t(11;14) translocation.
Sundaramoorthy P; Gasparetto C; Kang Y
Cancer Med; 2018 Jul; 7(7):3257-3268. PubMed ID: 29761903
[TBL] [Abstract][Full Text] [Related]
13. The BH3 mimetic drug ABT-737 induces apoptosis and acts synergistically with chemotherapeutic drugs in thyroid carcinoma cells.
Broecker-Preuss M; Becher-Boveleth N; Müller S; Mann K
Cancer Cell Int; 2016; 16():27. PubMed ID: 27042160
[TBL] [Abstract][Full Text] [Related]
14. The mTORC1/2 Inhibitor AZD8055 Strengthens the Efficiency of the MEK Inhibitor Trametinib to Reduce the Mcl-1/[Bim and Puma] ratio and to Sensitize Ovarian Carcinoma Cells to ABT-737.
Pétigny-Lechartier C; Duboc C; Jebahi A; Louis MH; Abeilard E; Denoyelle C; Gauduchon P; Poulain L; Villedieu M
Mol Cancer Ther; 2017 Jan; 16(1):102-115. PubMed ID: 27980105
[TBL] [Abstract][Full Text] [Related]
15. ABT-199-mediated inhibition of Bcl-2 as a potential therapeutic strategy for nasopharyngeal carcinoma.
Wang Y; Wang Y; Fan X; Song J; Wu H; Han J; Lu L; Weng X; Nie G
Biochem Biophys Res Commun; 2018 Sep; 503(3):1214-1220. PubMed ID: 30017199
[TBL] [Abstract][Full Text] [Related]
16. Hydroxychloroquine Promotes Bcl-xL Inhibition-induced Apoptosis in BxPC-3 Human Pancreatic Cancer Cells.
Hoque MM; Iida Y; Kotani H; Kartika ID; Harada M
Anticancer Res; 2022 Jul; 42(7):3495-3506. PubMed ID: 35790256
[TBL] [Abstract][Full Text] [Related]
17. BH3 mimetic ABT-737 and a proteasome inhibitor synergistically kill melanomas through Noxa-dependent apoptosis.
Miller LA; Goldstein NB; Johannes WU; Walton CH; Fujita M; Norris DA; Shellman YG
J Invest Dermatol; 2009 Apr; 129(4):964-71. PubMed ID: 18987671
[TBL] [Abstract][Full Text] [Related]
18. BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells.
Huang S; Sinicrope FA
Cancer Res; 2008 Apr; 68(8):2944-51. PubMed ID: 18413764
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of ITIH3 contributes to cisplatin-based chemotherapy resistance in ovarian carcinoma via the Bcl-2 mediated anti-apoptosis signaling pathway.
Liu Y; Shi L; Yuan C; Feng Y; Li M; Liu H; Chen X; Yao D; Wang Q
Oncol Lett; 2023 Feb; 25(2):61. PubMed ID: 36644154
[TBL] [Abstract][Full Text] [Related]
20. Select Bcl-2 antagonism restores chemotherapy sensitivity in high-risk neuroblastoma.
Tanos R; Karmali D; Nalluri S; Goldsmith KC
BMC Cancer; 2016 Feb; 16():97. PubMed ID: 26874859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
